A Low-Cost SARS-CoV-2 rRBD ELISA to Detect Serostatus in Ecuadorian Population with COVID-19.
Am J Trop Med Hyg
; 104(4): 1513-1515, 2021 Feb 25.
Article
in English
| MEDLINE | ID: covidwho-1102598
ABSTRACT
Laboratory diagnosis of the COVID-19 relies on RT-PCR to amplify specific fragments of SARS-CoV-2 genome. However, serological tests are required to determine the immune response elicited after infection. Here, we analyzed convalescent sera collected from positive individuals by RT-PCR to SARS-CoV-2 (n = 78), Zika (n = 20), dengue (n = 20), chikungunya (n = 54), intestinal parasites (n = 11), and HIV (n = 1), from different areas of Ecuador, with an in-house ELISA using a SARS-CoV-2 receptor binding domain recombinant (rRBD) antigen to detect IgG antibodies elicited by SARS-CoV-2 infection. Of the 78 samples positive for SARS-CoV-2 by RT-PCR, 73 showed high absorbance value compared with the cutoff and five were negative. All tested sera from other infections showed no reactivity. Sensitivity, specificity, positive predictive value, and negative predictive value were 93.6%, 100%, 100%, and 95.4%, respectively. This in-house anti-IgG rRBD ELISA offers an economic and simple alternative to determine IgG immune responses after SARS-CoV-2 infection.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Enzyme-Linked Immunosorbent Assay
/
Spike Glycoprotein, Coronavirus
/
COVID-19 Serological Testing
/
SARS-CoV-2
/
COVID-19
Type of study:
Diagnostic study
/
Observational study
/
Prognostic study
Limits:
Humans
Country/Region as subject:
South America
/
Ecuador
Language:
English
Journal:
Am J Trop Med Hyg
Year:
2021
Document Type:
Article
Affiliation country:
Ajtmh.20-1420
Similar
MEDLINE
...
LILACS
LIS